ImmunityBio (IBRX) Jefferies Global Healthcare Conference 2026 summary

Strategic vision and leadership

• Focus on executing the founder's vision to find cancer cures, leveraging platform technologies and global scientific leadership.

• Emphasis on durable, transformative therapies for cancer, aiming to shift standard treatment paradigms.

Platform technologies and product pipeline

• Fusion proteins (ANKTIVA) approved for non-muscle invasive bladder cancer in 35+ countries, with additional approval in Saudi Arabia for lung cancer.

• DNA vaccine vectors and cellular platforms (CAR-NK, M-ceNK) in clinical trials for multiple cancer types, including prostate, head, neck, and cervical cancers.

• Ongoing trials in 2025 and 2026 target broader indications beyond bladder cancer, including BCG-naive and papillary disease.

Clinical trial progress and regulatory milestones

• BCG-unresponsive CIS with and without papillary disease shows strong growth and global approvals; label expansion submitted with a PDUFA date of January 6, 2027.

• BCG-naive trial fully enrolled; interim analysis allowed closure for enrollment, with readout expected around September 2024.

• Two BCG strains (recombinant and Tokyo) now available, aiming to address U.S. shortages and expand approvals.